Adaptimmune Therapeutics plc (ADAP) ADS

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. The engineered T cell receptor (TCR) platform, which the Company is developing for personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers. It is focused on the commercialization of TECELRA, which is a genetically modified autologous T-cell immunotherapy indicated for the treatment of adults with advanced synovial sarcoma. Its second T-cell immunotherapy, letetresgene autoleucel (lete-cel), targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). It has filed an IND for ADP-5701 for a Phase I trial in Head and Neck Cancer in collaboration with Galapagos NV (Galapagos). It has two pre-clinical programs for the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).